APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Glioblastoma Treatment Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Glioblastoma Treatment Drugs Industry Growth and Trends Forecast to 2032

Report ID 173995330122 December 202591 pages

Choose your research edition.

Industry ResearchGlioblastoma Treatment Drugs Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Glioblastoma Treatment Drugs Industry Growth and Trends Forecast to 203291 pages · $3,450 USDMarket StructureGlobal Glioblastoma Treatment Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032189 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Glioblastoma Treatment Drugs Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Glioblastoma Treatment Drugs Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Glioblastoma Treatment Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Glioblastoma Treatment Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Glioblastoma Treatment Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Glioblastoma Treatment Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Glioblastoma Treatment Drugs include Sandoz, Merck & Co., Bristol-Myers Squibb Company, Sigma-Tau Pharmaceuticals, F. Hoffmann-La Roche AG, Emcure Pharmaceuticals Ltd. and Arbor Pharms LLC., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Glioblastoma Treatment Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Glioblastoma Treatment Drugs market size, estimates, and forecasts are presented in terms of sales volume (tons) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Glioblastoma Treatment Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Glioblastoma Treatment Drugs.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Glioblastoma Treatment Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Glioblastoma Treatment Drugs Market by Company

Sandoz

Merck & Co.

Bristol-Myers Squibb Company

Sigma-Tau Pharmaceuticals

F. Hoffmann-La Roche AG

Emcure Pharmaceuticals Ltd.

Arbor Pharms LLC.

Glioblastoma Treatment Drugs Segment by Type

Miscellaneous Antineoplastic

Alkylating Agents

VEGF/VEGFR Inhibitor

Glioblastoma Treatment Drugs Segment by Application

Diagnostic Centers

Long Term Care Center

Hospital

Cancer Research Organization

Glioblastoma Treatment Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Glioblastoma Treatment Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Glioblastoma Treatment Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Glioblastoma Treatment Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Glioblastoma Treatment Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Glioblastoma Treatment Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Miscellaneous Antineoplastic Table 2. Major Company of Alkylating Agents Table 3. Major Company of VEGF/VEGFR Inhibitor Table 4. Global Glioblastoma Treatment Drugs Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Glioblastoma Treatment Drugs Sales by Type (2021-2026) & (tons) Table 6. Global Glioblastoma Treatment Drugs Sales Market Share in Volume by Type (2021-2026) Table 7. Global Glioblastoma Treatment Drugs Sales by Type (2021-2026) & (US$ Million) Table 8. Global Glioblastoma Treatment Drugs Sales Market Share in Value by Type (2021-2026) Table 9. Global Glioblastoma Treatment Drugs Price by Type (2021-2026) & (US$/ton) Table 10. Global Glioblastoma Treatment Drugs Sales by Type (2027-2032) & (tons) Table 11. Global Glioblastoma Treatment Drugs Sales Market Share in Volume by Type (2027-2032) Table 12. Global Glioblastoma Treatment Drugs Sales by Type (2027-2032) & (US$ Million) Table 13. Global Glioblastoma Treatment Drugs Sales Market Share in Value by Type (2027-2032) Table 14. Global Glioblastoma Treatment Drugs Price by Type (2027-2032) & (US$/ton) Table 15. North America Glioblastoma Treatment Drugs Sales by Type (2021-2026) & (tons) Table 16. North America Glioblastoma Treatment Drugs Sales by Type (2021-2026) & (US$ Million) Table 17. Europe Glioblastoma Treatment Drugs Sales by Type (2021-2026) & (tons) Table 18. Europe Glioblastoma Treatment Drugs Sales by Type (2021-2026) & (US$ Million) Table 19. Asia-Pacific Glioblastoma Treatment Drugs Sales by Type (2021-2026) & (tons) Table 20. Asia-Pacific Glioblastoma Treatment Drugs Sales by Type (2021-2026) & (US$ Million) Table 21. Latin America Glioblastoma Treatment Drugs Sales by Type (2021-2026) & (tons) Table 22. Latin America Glioblastoma Treatment Drugs Sales by Type (2021-2026) & (US$ Million) Table 23. Middle East and Africa Glioblastoma Treatment Drugs Sales by Type (2021-2026) & (tons) Table 24. Middle East and Africa Glioblastoma Treatment Drugs Sales by Type (2021-2026) & (US$ Million) Table 25. Glioblastoma Treatment Drugs Industry Trends Table 26. Glioblastoma Treatment Drugs Industry Drivers Table 27. Glioblastoma Treatment Drugs Industry Opportunities and Challenges Table 28. Glioblastoma Treatment Drugs Industry Restraints Table 29. Global Glioblastoma Treatment Drugs Sales Revenue by Company (US$ Million) & (2021-2026) Table 30. Global Glioblastoma Treatment Drugs Revenue Market Share by Company (2021-2026) Table 31. Global Glioblastoma Treatment Drugs Sales by Company (2021-2026) & (tons) Table 32. Global Glioblastoma Treatment Drugs Sales Share by Company (2021-2026) Table 33. Global Glioblastoma Treatment Drugs Market Price by Company (2021-2026) & (US$/ton) Table 34. Global Glioblastoma Treatment Drugs Industry Company Ranking, 2024 VS 2025 VS 2026 Table 35. Global Glioblastoma Treatment Drugs Major Company Production Sites and Headquarters Table 36. Global Glioblastoma Treatment Drugs Company, Product Type & Application Table 37. Global Glioblastoma Treatment Drugs Company Establishment Date Table 38. Global Company Market Concentration Ratio (CR5 and HHI) Table 39. Global Glioblastoma Treatment Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 40. Global Glioblastoma Treatment Drugs Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 41. Global Glioblastoma Treatment Drugs Sales by Region (2021-2026) & (tons) Table 42. Global Glioblastoma Treatment Drugs Sales Market Share in Volume by Region (2021-2026) Table 43. Global Glioblastoma Treatment Drugs Sales by Region (2021-2026) & (US$ Million) Table 44. Global Glioblastoma Treatment Drugs Sales Market Share in Value by Region (2021-2026) Table 45. Global Glioblastoma Treatment Drugs Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 46. Global Glioblastoma Treatment Drugs Sales by Region (2027-2032) & (tons) Table 47. Global Glioblastoma Treatment Drugs Sales Market Share in Volume by Region (2027-2032) Table 48. Global Glioblastoma Treatment Drugs Sales by Region (2027-2032) & (US$ Million) Table 49. Global Glioblastoma Treatment Drugs Sales Market Share in Value by Region (2027-2032) Table 50. Global Glioblastoma Treatment Drugs Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2027-2032) Table 51. Global Glioblastoma Treatment Drugs Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 52. Global Glioblastoma Treatment Drugs Sales by Application (2021-2026) & (tons) Table 53. Global Glioblastoma Treatment Drugs Sales Market Share in Volume by Application (2021-2026) Table 54. Global Glioblastoma Treatment Drugs Sales by Application (2021-2026) & (US$ Million) Table 55. Global Glioblastoma Treatment Drugs Sales Market Share in Value by Application (2021-2026) Table 56. Global Glioblastoma Treatment Drugs Price by Application (2021-2026) & (US$/ton) Table 57. Global Glioblastoma Treatment Drugs Sales by Application (2027-2032) & (tons) Table 58. Global Glioblastoma Treatment Drugs Sales Market Share in Volume by Application (2027-2032) Table 59. Global Glioblastoma Treatment Drugs Sales by Application (2027-2032) & (US$ Million) Table 60. Global Glioblastoma Treatment Drugs Sales Market Share in Value by Application (2027-2032) Table 61. Global Glioblastoma Treatment Drugs Price by Application (2027-2032) & (US$/ton) Table 62. North America Glioblastoma Treatment Drugs Sales by Application (2021-2026) & (tons) Table 63. North America Glioblastoma Treatment Drugs Sales by Application (2021-2026) & (US$ Million) Table 64. Europe Glioblastoma Treatment Drugs Sales by Application (2021-2026) & (tons) Table 65. Europe Glioblastoma Treatment Drugs Sales by Application (2021-2026) & (US$ Million) Table 66. Asia-Pacific Glioblastoma Treatment Drugs Sales by Application (2021-2026) & (tons) Table 67. Asia-Pacific Glioblastoma Treatment Drugs Sales by Application (2021-2026) & (US$ Million) Table 68. Latin America Glioblastoma Treatment Drugs Sales by Application (2021-2026) & (tons) Table 69. Latin America Glioblastoma Treatment Drugs Sales by Application (2021-2026) & (US$ Million) Table 70. Middle East and Africa Glioblastoma Treatment Drugs Sales by Application (2021-2026) & (tons) Table 71. Middle East and Africa Glioblastoma Treatment Drugs Sales by Application (2021-2026) & (US$ Million) Table 72. Sandoz Company Information Table 73. Sandoz Business Overview Table 74. Sandoz Glioblastoma Treatment Drugs Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 75. Sandoz Glioblastoma Treatment Drugs Product Portfolio Table 76. Sandoz Recent Development Table 77. Merck & Co. Company Information Table 78. Merck & Co. Business Overview Table 79. Merck & Co. Glioblastoma Treatment Drugs Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 80. Merck & Co. Glioblastoma Treatment Drugs Product Portfolio Table 81. Merck & Co. Recent Development Table 82. Bristol-Myers Squibb Company Company Information Table 83. Bristol-Myers Squibb Company Business Overview Table 84. Bristol-Myers Squibb Company Glioblastoma Treatment Drugs Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 85. Bristol-Myers Squibb Company Glioblastoma Treatment Drugs Product Portfolio Table 86. Bristol-Myers Squibb Company Recent Development Table 87. Sigma-Tau Pharmaceuticals Company Information Table 88. Sigma-Tau Pharmaceuticals Business Overview Table 89. Sigma-Tau Pharmaceuticals Glioblastoma Treatment Drugs Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 90. Sigma-Tau Pharmaceuticals Glioblastoma Treatment Drugs Product Portfolio Table 91. Sigma-Tau Pharmaceuticals Recent Development Table 92. F. Hoffmann-La Roche AG Company Information Table 93. F. Hoffmann-La Roche AG Business Overview Table 94. F. Hoffmann-La Roche AG Glioblastoma Treatment Drugs Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 95. F. Hoffmann-La Roche AG Glioblastoma Treatment Drugs Product Portfolio Table 96. F. Hoffmann-La Roche AG Recent Development Table 97. Emcure Pharmaceuticals Ltd. Company Information Table 98. Emcure Pharmaceuticals Ltd. Business Overview Table 99. Emcure Pharmaceuticals Ltd. Glioblastoma Treatment Drugs Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 100. Emcure Pharmaceuticals Ltd. Glioblastoma Treatment Drugs Product Portfolio Table 101. Emcure Pharmaceuticals Ltd. Recent Development Table 102. Arbor Pharms LLC. Company Information Table 103. Arbor Pharms LLC. Business Overview Table 104. Arbor Pharms LLC. Glioblastoma Treatment Drugs Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 105. Arbor Pharms LLC. Glioblastoma Treatment Drugs Product Portfolio Table 106. Arbor Pharms LLC. Recent Development Table 107. North America Glioblastoma Treatment Drugs Market Size Growth Rate (CAGR) by Country (tons): 2021 VS 2025 VS 2032 Table 108. North America Glioblastoma Treatment Drugs Sales by Country (2021-2026) & (tons) Table 109. North America Glioblastoma Treatment Drugs Sales Market Share by Country (2021-2026) Table 110. North America Glioblastoma Treatment Drugs Sales Forecast by Country (2027-2032) & (tons) Table 111. North America Glioblastoma Treatment Drugs Sales Market Share Forecast by Country (2027-2032) Table 112. North America Glioblastoma Treatment Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 113. North America Glioblastoma Treatment Drugs Market Size by Country (2021-2026) & (US$ Million) Table 114. North America Glioblastoma Treatment Drugs Market Share by Country (2021-2026) Table 115. North America Glioblastoma Treatment Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 116. North America Glioblastoma Treatment Drugs Market Share Forecast by Country (2027-2032) Table 117. Europe Glioblastoma Treatment Drugs Market Size Growth Rate (CAGR) by Country (tons): 2021 VS 2025 VS 2032 Table 118. Europe Glioblastoma Treatment Drugs Sales by Country (2021-2026) & (tons) Table 119. Europe Glioblastoma Treatment Drugs Sales Market Share by Country (2021-2026) Table 120. Europe Glioblastoma Treatment Drugs Sales Forecast by Country (2027-2032) & (tons) Table 121. Europe Glioblastoma Treatment Drugs Sales Market Share Forecast by Country (2027-2032) Table 122. Europe Glioblastoma Treatment Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 123. Europe Glioblastoma Treatment Drugs Market Size by Country (2021-2026) & (US$ Million) Table 124. Europe Glioblastoma Treatment Drugs Market Share by Country (2021-2026) Table 125. Europe Glioblastoma Treatment Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 126. Europe Glioblastoma Treatment Drugs Market Share Forecast by Country (2027-2032) Table 127. Asia-Pacific Glioblastoma Treatment Drugs Market Size Growth Rate (CAGR) by Country (tons): 2021 VS 2025 VS 2032 Table 128. Asia-Pacific Glioblastoma Treatment Drugs Sales by Country (2021-2026) & (tons) Table 129. Asia-Pacific Glioblastoma Treatment Drugs Sales Market Share by Country (2021-2026) Table 130. Asia-Pacific Glioblastoma Treatment Drugs Sales Forecast by Country (2027-2032) & (tons) Table 131. Asia-Pacific Glioblastoma Treatment Drugs Sales Market Share Forecast by Country (2027-2032) Table 132. Asia-Pacific Glioblastoma Treatment Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 133. Asia-Pacific Glioblastoma Treatment Drugs Market Size by Country (2021-2026) & (US$ Million) Table 134. Asia-Pacific Glioblastoma Treatment Drugs Market Share by Country (2021-2026) Table 135. Asia-Pacific Glioblastoma Treatment Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 136. Asia-Pacific Glioblastoma Treatment Drugs Market Share Forecast by Country (2027-2032) Table 137. Latin America Glioblastoma Treatment Drugs Market Size Growth Rate (CAGR) by Country (tons): 2021 VS 2025 VS 2032 Table 138. Latin America Glioblastoma Treatment Drugs Sales by Country (2021-2026) & (tons) Table 139. Latin America Glioblastoma Treatment Drugs Sales Market Share by Country (2021-2026) Table 140. Latin America Glioblastoma Treatment Drugs Sales Forecast by Country (2027-2032) & (tons) Table 141. Latin America Glioblastoma Treatment Drugs Sales Market Share Forecast by Country (2027-2032) Table 142. Latin America Glioblastoma Treatment Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 143. Latin America Glioblastoma Treatment Drugs Market Size by Country (2021-2026) & (US$ Million) Table 144. Latin America Glioblastoma Treatment Drugs Market Share by Country (2021-2026) Table 145. Latin America Glioblastoma Treatment Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 146. Latin America Glioblastoma Treatment Drugs Market Share Forecast by Country (2027-2032) Table 147. Middle East and Africa Glioblastoma Treatment Drugs Market Size Growth Rate (CAGR) by Country (tons): 2021 VS 2025 VS 2032 Table 148. Middle East and Africa Glioblastoma Treatment Drugs Sales by Country (2021-2026) & (tons) Table 149. Middle East and Africa Glioblastoma Treatment Drugs Sales Market Share by Country (2021-2026) Table 150. Middle East and Africa Glioblastoma Treatment Drugs Sales Forecast by Country (2027-2032) & (tons) Table 151. Middle East and Africa Glioblastoma Treatment Drugs Sales Market Share Forecast by Country (2027-2032) Table 152. Middle East and Africa Glioblastoma Treatment Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 153. Middle East and Africa Glioblastoma Treatment Drugs Market Size by Country (2021-2026) & (US$ Million) Table 154. Middle East and Africa Glioblastoma Treatment Drugs Market Share by Country (2021-2026) Table 155. Middle East and Africa Glioblastoma Treatment Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 156. Middle East and Africa Glioblastoma Treatment Drugs Market Share Forecast by Country (2027-2032) Table 157. Key Raw Materials Table 158. Raw Materials Key Suppliers Table 159. Glioblastoma Treatment Drugs Distributors List Table 160. Glioblastoma Treatment Drugs Customers List Table 161. Research Programs/Design for This Report Table 162. Authors List of This Report Table 163. Secondary Sources Table 164. Primary Sources List of Figures Figure 1. Glioblastoma Treatment Drugs Image Figure 2. Global Glioblastoma Treatment Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Glioblastoma Treatment Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Glioblastoma Treatment Drugs Sales (2021-2032) & (tons) Figure 5. Miscellaneous Antineoplastic Image Figure 6. Global Miscellaneous Antineoplastic Sales YoY Growth (2021-2032) & (tons) Figure 7. Alkylating Agents Image Figure 8. Global Alkylating Agents Sales YoY Growth (2021-2032) & (tons) Figure 9. VEGF/VEGFR Inhibitor Image Figure 10. Global VEGF/VEGFR Inhibitor Sales YoY Growth (2021-2032) & (tons) Figure 11. Global Glioblastoma Treatment Drugs Market Size Overview by Type (2021-2032) & (US$ Million) Figure 12. Global Glioblastoma Treatment Drugs Market Share by Type 2025 VS 2032 Figure 13. North America Glioblastoma Treatment Drugs Sales Market Share in Volume by Type in 2025 Figure 14. North America Glioblastoma Treatment Drugs Sales Market Share in Value by Type in 2025 Figure 15. Europe Glioblastoma Treatment Drugs Sales Market Share in Volume by Type in 2025 Figure 16. Europe Glioblastoma Treatment Drugs Sales Market Share in Value by Type in 2025 Figure 17. Asia-Pacific Glioblastoma Treatment Drugs Sales Market Share in Volume by Type in 2025 Figure 18. Asia-Pacific Glioblastoma Treatment Drugs Sales Market Share in Value by Type in 2025 Figure 19. Latin America Glioblastoma Treatment Drugs Sales Market Share in Volume by Type in 2025 Figure 20. Latin America Glioblastoma Treatment Drugs Sales Market Share in Value by Type in 2025 Figure 21. Middle East and Africa Glioblastoma Treatment Drugs Sales Market Share in Volume by Type in 2025 Figure 22. Middle East and Africa Glioblastoma Treatment Drugs Sales Market Share in Value by Type in 2025 Figure 23. Global Top 5 and 10 Glioblastoma Treatment Drugs Players Market Share by Revenue in 2025 Figure 24. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. Diagnostic Centers Image Figure 26. Global Diagnostic Centers Sales YoY Growth (2021-2032) & (tons) Figure 27. Long Term Care Center Image Figure 28. Global Long Term Care Center Sales YoY Growth (2021-2032) & (tons) Figure 29. Hospital Image Figure 30. Global Hospital Sales YoY Growth (2021-2032) & (tons) Figure 31. Cancer Research Organization Image Figure 32. Global Cancer Research Organization Sales YoY Growth (2021-2032) & (tons) Figure 33. Global Glioblastoma Treatment Drugs Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Glioblastoma Treatment Drugs Market Share by Application 2025 VS 2032 Figure 35. North America Glioblastoma Treatment Drugs Sales Market Share in Volume by Application in 2025 Figure 36. North America Glioblastoma Treatment Drugs Sales Market Share in Value by Application in 2025 Figure 37. Europe Glioblastoma Treatment Drugs Sales Market Share in Volume by Application in 2025 Figure 38. Europe Glioblastoma Treatment Drugs Sales Market Share in Value by Application in 2025 Figure 39. Asia-Pacific Glioblastoma Treatment Drugs Sales Market Share in Volume by Application in 2025 Figure 40. Asia-Pacific Glioblastoma Treatment Drugs Sales Market Share in Value by Application in 2025 Figure 41. Latin America Glioblastoma Treatment Drugs Sales Market Share in Volume by Application in 2025 Figure 42. Latin America Glioblastoma Treatment Drugs Sales Market Share in Value by Application in 2025 Figure 43. Middle East and Africa Glioblastoma Treatment Drugs Sales Market Share in Volume by Application in 2025 Figure 44. Middle East and Africa Glioblastoma Treatment Drugs Sales Market Share in Value by Application in 2025 Figure 45. North America Glioblastoma Treatment Drugs Sales by Country: 2021 VS 2025 VS 2032 (tons) Figure 46. North America Glioblastoma Treatment Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. North America Glioblastoma Treatment Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. North America Glioblastoma Treatment Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Glioblastoma Treatment Drugs Sales by Country: 2021 VS 2025 VS 2032 (tons) Figure 50. Europe Glioblastoma Treatment Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Glioblastoma Treatment Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Europe Glioblastoma Treatment Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Glioblastoma Treatment Drugs Sales by Country: 2021 VS 2025 VS 2032 (tons) Figure 54. Asia-Pacific Glioblastoma Treatment Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Glioblastoma Treatment Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Asia-Pacific Glioblastoma Treatment Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Glioblastoma Treatment Drugs Sales by Country: 2021 VS 2025 VS 2032 (tons) Figure 58. Latin America Glioblastoma Treatment Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Glioblastoma Treatment Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Latin America Glioblastoma Treatment Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Glioblastoma Treatment Drugs Sales by Country: 2021 VS 2025 VS 2032 (tons) Figure 62. Middle East and Africa Glioblastoma Treatment Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Glioblastoma Treatment Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Middle East and Africa Glioblastoma Treatment Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Glioblastoma Treatment Drugs Value Chain Figure 66. Key Raw Materials Price Figure 67. Manufacturing Cost Structure Figure 68. Glioblastoma Treatment Drugs Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Miscellaneous Antineoplastic
  • Alkylating Agents
  • VEGF/VEGFR Inhibitor
Applications
  • Diagnostic Centers
  • Long Term Care Center
  • Hospital
  • Cancer Research Organization
Companies covered
  • Sandoz
  • Merck & Co.
  • Bristol-Myers Squibb Company
  • Sigma-Tau Pharmaceuticals
  • F. Hoffmann-La Roche AG
  • Emcure Pharmaceuticals Ltd.
  • Arbor Pharms LLC.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Glioblastoma Treatment Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Glioblastoma Treatment Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Glioblastoma Treatment Drugs Market by Type
  6. 1.3.1 Miscellaneous Antineoplastic
  7. 1.3.2 Alkylating Agents
  8. 1.3.3 VEGF/VEGFR Inhibitor
  9. 1.4 Global Glioblastoma Treatment Drugs Market Size by Type
  10. 1.4.1 Global Glioblastoma Treatment Drugs Market Size Overview by Type (2021-2032)
  11. 1.4.2 Global Glioblastoma Treatment Drugs Historic Market Size Review by Type (2021-2026)
  12. 1.4.3 Global Glioblastoma Treatment Drugs Forecasted Market Size by Type (2027-2032)
  13. 1.5 Key Regions Market Size by Type
  14. 1.5.1 North America Glioblastoma Treatment Drugs Sales Breakdown by Type (2021-2026)
  15. 1.5.2 Europe Glioblastoma Treatment Drugs Sales Breakdown by Type (2021-2026)
  16. 1.5.3 Asia-Pacific Glioblastoma Treatment Drugs Sales Breakdown by Type (2021-2026)
  17. 1.5.4 South America Glioblastoma Treatment Drugs Sales Breakdown by Type (2021-2026)
  18. 1.5.5 Middle East and Africa Glioblastoma Treatment Drugs Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Glioblastoma Treatment Drugs Industry Trends
  2. 2.2 Glioblastoma Treatment Drugs Industry Drivers
  3. 2.3 Glioblastoma Treatment Drugs Industry Opportunities and Challenges
  4. 2.4 Glioblastoma Treatment Drugs Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Glioblastoma Treatment Drugs Revenue (2021-2026)
  2. 3.2 Global Top Players by Glioblastoma Treatment Drugs Sales (2021-2026)
  3. 3.3 Global Top Players by Glioblastoma Treatment Drugs Price (2021-2026)
  4. 3.4 Global Glioblastoma Treatment Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Glioblastoma Treatment Drugs Major Company Production Sites & Headquarters
  6. 3.6 Global Glioblastoma Treatment Drugs Company, Product Type & Application
  7. 3.7 Global Glioblastoma Treatment Drugs Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Glioblastoma Treatment Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Glioblastoma Treatment Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Glioblastoma Treatment Drugs Tier 1, Tier 2, and Tier 3
4 Glioblastoma Treatment Drugs Regional Status and Outlook
  1. 4.1 Global Glioblastoma Treatment Drugs Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Glioblastoma Treatment Drugs Historic Market Size by Region
  3. 4.2.1 Global Glioblastoma Treatment Drugs Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Glioblastoma Treatment Drugs Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Glioblastoma Treatment Drugs Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Glioblastoma Treatment Drugs Forecasted Market Size by Region
  7. 4.3.1 Global Glioblastoma Treatment Drugs Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Glioblastoma Treatment Drugs Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Glioblastoma Treatment Drugs Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Glioblastoma Treatment Drugs by Application
  1. 5.1 Glioblastoma Treatment Drugs Market by Application
  2. 5.1.1 Diagnostic Centers
  3. 5.1.2 Long Term Care Center
  4. 5.1.3 Hospital
  5. 5.1.4 Cancer Research Organization
  6. 5.2 Global Glioblastoma Treatment Drugs Market Size by Application
  7. 5.2.1 Global Glioblastoma Treatment Drugs Market Size Overview by Application (2021-2032)
  8. 5.2.2 Global Glioblastoma Treatment Drugs Historic Market Size Review by Application (2021-2026)
  9. 5.2.3 Global Glioblastoma Treatment Drugs Forecasted Market Size by Application (2027-2032)
  10. 5.3 Key Regions Market Size by Application
  11. 5.3.1 North America Glioblastoma Treatment Drugs Sales Breakdown by Application (2021-2026)
  12. 5.3.2 Europe Glioblastoma Treatment Drugs Sales Breakdown by Application (2021-2026)
  13. 5.3.3 Asia-Pacific Glioblastoma Treatment Drugs Sales Breakdown by Application (2021-2026)
  14. 5.3.4 South America Glioblastoma Treatment Drugs Sales Breakdown by Application (2021-2026)
  15. 5.3.5 Middle East and Africa Glioblastoma Treatment Drugs Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Sandoz
  2. 6.1.1 Sandoz Company Information
  3. 6.1.2 Sandoz Business Overview
  4. 6.1.3 Sandoz Glioblastoma Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Sandoz Glioblastoma Treatment Drugs Product Portfolio
  6. 6.1.5 Sandoz Recent Developments
  7. 6.2 Merck & Co.
  8. 6.2.1 Merck & Co. Company Information
  9. 6.2.2 Merck & Co. Business Overview
  10. 6.2.3 Merck & Co. Glioblastoma Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Merck & Co. Glioblastoma Treatment Drugs Product Portfolio
  12. 6.2.5 Merck & Co. Recent Developments
  13. 6.3 Bristol-Myers Squibb Company
  14. 6.3.1 Bristol-Myers Squibb Company Company Information
  15. 6.3.2 Bristol-Myers Squibb Company Business Overview
  16. 6.3.3 Bristol-Myers Squibb Company Glioblastoma Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Bristol-Myers Squibb Company Glioblastoma Treatment Drugs Product Portfolio
  18. 6.3.5 Bristol-Myers Squibb Company Recent Developments
  19. 6.4 Sigma-Tau Pharmaceuticals
  20. 6.4.1 Sigma-Tau Pharmaceuticals Company Information
  21. 6.4.2 Sigma-Tau Pharmaceuticals Business Overview
  22. 6.4.3 Sigma-Tau Pharmaceuticals Glioblastoma Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Sigma-Tau Pharmaceuticals Glioblastoma Treatment Drugs Product Portfolio
  24. 6.4.5 Sigma-Tau Pharmaceuticals Recent Developments
  25. 6.5 F. Hoffmann-La Roche AG
  26. 6.5.1 F. Hoffmann-La Roche AG Company Information
  27. 6.5.2 F. Hoffmann-La Roche AG Business Overview
  28. 6.5.3 F. Hoffmann-La Roche AG Glioblastoma Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 F. Hoffmann-La Roche AG Glioblastoma Treatment Drugs Product Portfolio
  30. 6.5.5 F. Hoffmann-La Roche AG Recent Developments
  31. 6.6 Emcure Pharmaceuticals Ltd.
  32. 6.6.1 Emcure Pharmaceuticals Ltd. Company Information
  33. 6.6.2 Emcure Pharmaceuticals Ltd. Business Overview
  34. 6.6.3 Emcure Pharmaceuticals Ltd. Glioblastoma Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Emcure Pharmaceuticals Ltd. Glioblastoma Treatment Drugs Product Portfolio
  36. 6.6.5 Emcure Pharmaceuticals Ltd. Recent Developments
  37. 6.7 Arbor Pharms LLC.
  38. 6.7.1 Arbor Pharms LLC. Company Information
  39. 6.7.2 Arbor Pharms LLC. Business Overview
  40. 6.7.3 Arbor Pharms LLC. Glioblastoma Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Arbor Pharms LLC. Glioblastoma Treatment Drugs Product Portfolio
  42. 6.7.5 Arbor Pharms LLC. Recent Developments
7 North America by Country
  1. 7.1 North America Glioblastoma Treatment Drugs Sales by Country
  2. 7.1.1 North America Glioblastoma Treatment Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Glioblastoma Treatment Drugs Sales by Country (2021-2026)
  4. 7.1.3 North America Glioblastoma Treatment Drugs Sales Forecast by Country (2027-2032)
  5. 7.2 North America Glioblastoma Treatment Drugs Market Size by Country
  6. 7.2.1 North America Glioblastoma Treatment Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Glioblastoma Treatment Drugs Market Size by Country (2021-2026)
  8. 7.2.3 North America Glioblastoma Treatment Drugs Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Glioblastoma Treatment Drugs Sales by Country
  2. 8.1.1 Europe Glioblastoma Treatment Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Glioblastoma Treatment Drugs Sales by Country (2021-2026)
  4. 8.1.3 Europe Glioblastoma Treatment Drugs Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Glioblastoma Treatment Drugs Market Size by Country
  6. 8.2.1 Europe Glioblastoma Treatment Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Glioblastoma Treatment Drugs Market Size by Country (2021-2026)
  8. 8.2.3 Europe Glioblastoma Treatment Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Glioblastoma Treatment Drugs Sales by Country
  2. 9.1.1 Asia-Pacific Glioblastoma Treatment Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Glioblastoma Treatment Drugs Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Glioblastoma Treatment Drugs Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Glioblastoma Treatment Drugs Market Size by Country
  6. 9.2.1 Asia-Pacific Glioblastoma Treatment Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Glioblastoma Treatment Drugs Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Glioblastoma Treatment Drugs Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Glioblastoma Treatment Drugs Sales by Country
  2. 10.1.1 South America Glioblastoma Treatment Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Glioblastoma Treatment Drugs Sales by Country (2021-2026)
  4. 10.1.3 South America Glioblastoma Treatment Drugs Sales Forecast by Country (2027-2032)
  5. 10.2 South America Glioblastoma Treatment Drugs Market Size by Country
  6. 10.2.1 South America Glioblastoma Treatment Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Glioblastoma Treatment Drugs Market Size by Country (2021-2026)
  8. 10.2.3 South America Glioblastoma Treatment Drugs Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Glioblastoma Treatment Drugs Sales by Country
  2. 11.1.1 Middle East and Africa Glioblastoma Treatment Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Glioblastoma Treatment Drugs Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Glioblastoma Treatment Drugs Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Glioblastoma Treatment Drugs Market Size by Country
  6. 11.2.1 Middle East and Africa Glioblastoma Treatment Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Glioblastoma Treatment Drugs Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Glioblastoma Treatment Drugs Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Glioblastoma Treatment Drugs Value Chain Analysis
  2. 12.1.1 Glioblastoma Treatment Drugs Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Glioblastoma Treatment Drugs Production Mode & Process
  7. 12.2 Glioblastoma Treatment Drugs Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Glioblastoma Treatment Drugs Distributors
  10. 12.2.3 Glioblastoma Treatment Drugs Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst